<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01742390</url>
  </required_header>
  <id_info>
    <org_study_id>ARI_IIT_01/02</org_study_id>
    <nct_id>NCT01742390</nct_id>
  </id_info>
  <brief_title>A Multicenter Study to Evaluate the Effects of Switching to Aripiprazole 12 Weeks on the Sexual Dysfunction From Risperidone or Paliperidone in Patients With Schizophrenia Spectrum Disorders or Bipolar Spectrum Disorders</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Si Tianmei</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial designed to investigate the effect of switching to aripiprazole from risperidone
      or paliperidone on reverse prolactin level, and consequently improve sexual dysfunction in
      adult patients with schizophrenia spectrum disorders and bipolar spectrum disorders.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in severity of sexual/reproductive system dysfunction at 12 weeks</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of absence of sexual/reproductive system dysfunction on the UKU side effect rating scale or ASEX</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Sexual Dysfunction</condition>
  <condition>Hyperprolactinemia</condition>
  <arm_group>
    <arm_group_label>Aripiprazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Plateau switch to aripiprazole (ARI) from risperidone (RIS) or paliperidone (PALI)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>risperidone or paliperidone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Stay on risperidone (RIS) or paliperidone (PALI)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aripiprazole</intervention_name>
    <description>Plateau switch to aripiprazole (ARI) from risperidone (RIS) or paliperidone (PALI)</description>
    <arm_group_label>Aripiprazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>risperidone or paliperidone</intervention_name>
    <arm_group_label>risperidone or paliperidone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age: 12-55 years (male), 12-40 (female)

          2. Diagnosis: Schizophrenia spectrum disorders &amp; bipolar spectrum disorders (only Korea)
             by DSM-IV-TR

          3. Receiving RIS or PALI with stable dose for &gt; 1 month by their physician;

          4. Prolactin level Adult: &gt; 20 ng/ml (male), 25 ng/ml (female) Child/Adolescent: &gt; 20
             ng/ml (male, female)

          5. Children and adolescents (age: 12~17 years) having more than one sexual system
             dysfunction measured by 5 of the 48 UKU items (galactorrhoea, gynecomastia and
             erectile dysfunction for male, galactorrhea, amenorrhoea/oligomenorrhoea, and dry
             vagina for female) or Adults (age: 18~55 years) who are considered to have
             sexual/reproductive dysfunction if they had either a total score of 19 or higher; a
             score of 5 or higher on one question; or a score of 4 or higher on 3 questions.

          6. Subjects who have consented to participate by signing an informed consent form.

        Exclusion Criteria:

          1. Medical disorder or psychiatric comorbidity or condition known to affect prolactin,
             sex hormone balance or bone metabolism (i.e., unstable medical disease, Cushing's
             disease, chronic renal failure, thyroid dysfunction, eating disorder)

          2. History of hematological and/or solid malignancies

          3. Physical or functional obstruction to food intake or impaired digestive/absorptive
             function

          4. Known hypersensitivity to any study medication (risperidone, paliperidone, and
             aripiprazole)

          5. Insulin requiring diabetes mellitus or poorly controlled diabetes mellitus (HbA1c &gt; 9%
             or change of antidiabetics treatment within the 12weeks prior to screening)

          6. Uncontrolled hypertension (SBP/DBP 140/90 mmHg), congestive heart failure (NYHA class
             III or IV), other significant cardiovascular illness (myocardial infarction, unstable
             angina, cardiac arrhythmia etc.)

          7. Baseline QTc interval of &gt; 450 msec

          8. Hepatic and/or renal dysfunction

        1) Bilirubin level ≥ 1.5 upper normal limits 2) AST/ALT ≥ 3 UNL or 3) Serum creatinine ≥
        1.5 9. Any patient hospitalized for acute exacerbation of their condition within 2 months
        of randomization 10. Recent (within the past 1 month) or planned treatment with prohibited
        medications in the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Tianmei Si, MD.</last_name>
    <phone>861082801948</phone>
    <email>si.tian-mei@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institute of mental health, Peking University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100191</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tianmei Si, MD.</last_name>
      <phone>8610-82801948</phone>
      <email>si.tian-mei@163.cm</email>
    </contact>
    <investigator>
      <last_name>Tianmei Si, MD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The first hospital of Hebei Province University</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xueyi Wang, Professor</last_name>
      <phone>0311-85917290</phone>
    </contact>
    <investigator>
      <last_name>Xueyi Wang</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 22, 2012</study_first_submitted>
  <study_first_submitted_qc>December 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2012</study_first_posted>
  <last_update_submitted>March 13, 2013</last_update_submitted>
  <last_update_submitted_qc>March 13, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 14, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Peking University</investigator_affiliation>
    <investigator_full_name>Si Tianmei</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>schizophrenia</keyword>
  <keyword>risperidone</keyword>
  <keyword>paliperidone</keyword>
  <keyword>aripiprazole</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperprolactinemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Risperidone</mesh_term>
    <mesh_term>Paliperidone Palmitate</mesh_term>
    <mesh_term>Aripiprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

